FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W12291014> ?p ?o ?g. }

• W12291014 endingPage "407" @default.
• W12291014 startingPage "407" @default.
• W12291014 abstract "Abstract Background Conflicting results have emerged, especially with respect to the impact on overall survival (OS), from trials evaluating lenalidomide maintenance (LM) therapy after induction therapy alone or post-autologous stem cell transplant (ASCT) in multiple myeloma (MM). We performed a systematic review and meta-analysis of existing outcome data from LM trials to evaluate role of lenalidomide as maintenance strategy in MM. Patients and methods A comprehensive search of electronic databases and abstracts through June 2013 was performed to identify randomized controlled trials (RCTs) that compared LM vs. placebo/no maintenance. Single arm studies were excluded. Pooled hazard ratio (HR) or odds ratio (OR) estimates with 95% confidence intervals (CIs) were calculated using the random-effects model for clinical endpoints of progression free survival (PFS), OS, response rate (RR) and adverse events (AEs), including second primary malignancies (SPMs). Analyses were performed using Comprehensive Meta-Analysis Software Version 2. We assessed between-study heterogeneity with the Cochran Q test and quantified its extent with the I2 statistic. Results Overall, five RCTs, with data extractable from four phase III trials (3 publications and 1 abstract) were identified (n= 1935). All studies were RCTs with an adequate randomization. MRC MM XI study was excluded from analyses as survival data are not available. Two placebo controlled trials (IFM 05-02, CALGB 100104) addressed the role of LM post-ASCT, one placebo-controlled trial (MM-015) studied LM therapy in the non-transplant setting and the remaining trial (RV-MM-PI209) had a 2 X 2 design comprising of both ASCT and non-transplant randomized arms followed by a second randomization of LM versus no maintenance. There was no heterogeneity for estimate of PFS results (Cochran Q, p=0.68; I2=0%), but considerable heterogeneity for estimate of OS (Cochran Q, p=0.09; I2= 55%), among the studies. There was significant prolongation of both PFS (HR 0.49, 95% CI, 0.41–0.58, p<0.001) and OS (HR 0.77, 95% CI, 0.62–0.95, p=0.013) with LM vs. placebo/no maintenance (Figure 1). Best response during maintenance was reported only in 2 studies and odds of responding (very good partial response or better) were not significantly different with LM (OR 1.28, p=0.3). Grade 3-4 AEs data were available from 3 trials for calculation of pooled OR with LM compared with placebo. We observed a nearly two-fold increase in the risk of SPMs with LM (OR 1.99; 95% CI, 1.31–3.04; p=0.001). Patients on LM were more likely to have grade 3-4 AEs than placebo: neutropenia (OR 4.9, p<0.001), thrombocytopenia (OR 2.7, p<0.001), fatigue (OR 2.3, p=0.01) and venous thromboembolism (OR 3.2, p=0.02). Odds of discontinuing treatment were also significantly higher in patients on lenalidomide (OR 2.9, p<0.001). Conclusions Meta-analysis of RCTs demonstrates significant improvement in PFS and modest improvement in OS with LM. There is an increased risk of grade 3-4 adverse effects, including SPMs with LM. Substantial heterogeneity for estimate of OS among protocols is a limitation of this analysis. Lack of uniform access to lenalidomide upon disease progression in the placebo/no maintenance arms of the constituent studies should be taken into account while interpreting aggregate effect estimates for OS in this meta-analysis. OS: Cochran Q p=0.09, I2=55%, substantial heterogeneity PFS: Cochran Q p=0.68, I2=0%, minimal heterogeneity Disclosures: Off Label Use: Lenalidomide for maintenance therapy in multiple myeloma. Kumar:Merck: Consultancy, Honoraria; Celgene: Consultancy, Research Funding; Millennium: The Takeda Oncology Company: Research Funding; Novartis: Research Funding; Genzyme: Research Funding. Dispenzieri:Celgene, Millenium, Jansenn, Pfizer: Research Funding. Bergsagel:Onyx: Consultancy. Lacy:Celgene Corporation: Research Funding." @default.
• W12291014 created "2016-06-24" @default.
• W12291014 creator A5000308170 @default.
• W12291014 creator A5004436275 @default.
• W12291014 creator A5012403700 @default.
• W12291014 creator A5012884078 @default.
• W12291014 creator A5023193953 @default.
• W12291014 creator A5026574827 @default.
• W12291014 creator A5033220547 @default.
• W12291014 creator A5035847062 @default.
• W12291014 creator A5044733637 @default.
• W12291014 creator A5047421947 @default.
• W12291014 creator A5054957898 @default.
• W12291014 creator A5072347487 @default.
• W12291014 creator A5076611748 @default.
• W12291014 creator A5091287816 @default.
• W12291014 date "2013-11-15" @default.
• W12291014 modified "2023-09-28" @default.
• W12291014 title "Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials" @default.
• W12291014 doi "https://doi.org/10.1182/blood.v122.21.407.407" @default.
• W12291014 hasPublicationYear "2013" @default.
• W12291014 type Work @default.
• W12291014 sameAs 12291014 @default.
• W12291014 citedByCount "13" @default.
• W12291014 countsByYear W122910142014 @default.
• W12291014 countsByYear W122910142016 @default.
• W12291014 countsByYear W122910142017 @default.
• W12291014 countsByYear W122910142019 @default.
• W12291014 countsByYear W122910142020 @default.
• W12291014 countsByYear W122910142021 @default.
• W12291014 countsByYear W122910142022 @default.
• W12291014 crossrefType "journal-article" @default.
• W12291014 hasAuthorship W12291014A5000308170 @default.
• W12291014 hasAuthorship W12291014A5004436275 @default.
• W12291014 hasAuthorship W12291014A5012403700 @default.
• W12291014 hasAuthorship W12291014A5012884078 @default.
• W12291014 hasAuthorship W12291014A5023193953 @default.
• W12291014 hasAuthorship W12291014A5026574827 @default.
• W12291014 hasAuthorship W12291014A5033220547 @default.
• W12291014 hasAuthorship W12291014A5035847062 @default.
• W12291014 hasAuthorship W12291014A5044733637 @default.
• W12291014 hasAuthorship W12291014A5047421947 @default.
• W12291014 hasAuthorship W12291014A5054957898 @default.
• W12291014 hasAuthorship W12291014A5072347487 @default.
• W12291014 hasAuthorship W12291014A5076611748 @default.
• W12291014 hasAuthorship W12291014A5091287816 @default.
• W12291014 hasConcept C126322002 @default.
• W12291014 hasConcept C142724271 @default.
• W12291014 hasConcept C143998085 @default.
• W12291014 hasConcept C168563851 @default.
• W12291014 hasConcept C204787440 @default.
• W12291014 hasConcept C207103383 @default.
• W12291014 hasConcept C27081682 @default.
• W12291014 hasConcept C2776063141 @default.
• W12291014 hasConcept C2776364478 @default.
• W12291014 hasConcept C2776694085 @default.
• W12291014 hasConcept C2778283404 @default.
• W12291014 hasConcept C44249647 @default.
• W12291014 hasConcept C535046627 @default.
• W12291014 hasConcept C71924100 @default.
• W12291014 hasConcept C95190672 @default.
• W12291014 hasConceptScore W12291014C126322002 @default.
• W12291014 hasConceptScore W12291014C142724271 @default.
• W12291014 hasConceptScore W12291014C143998085 @default.
• W12291014 hasConceptScore W12291014C168563851 @default.
• W12291014 hasConceptScore W12291014C204787440 @default.
• W12291014 hasConceptScore W12291014C207103383 @default.
• W12291014 hasConceptScore W12291014C27081682 @default.
• W12291014 hasConceptScore W12291014C2776063141 @default.
• W12291014 hasConceptScore W12291014C2776364478 @default.
• W12291014 hasConceptScore W12291014C2776694085 @default.
• W12291014 hasConceptScore W12291014C2778283404 @default.
• W12291014 hasConceptScore W12291014C44249647 @default.
• W12291014 hasConceptScore W12291014C535046627 @default.
• W12291014 hasConceptScore W12291014C71924100 @default.
• W12291014 hasConceptScore W12291014C95190672 @default.
• W12291014 hasIssue "21" @default.
• W12291014 hasLocation W122910141 @default.
• W12291014 hasOpenAccess W12291014 @default.
• W12291014 hasPrimaryLocation W122910141 @default.
• W12291014 hasRelatedWork W1900595920 @default.
• W12291014 hasRelatedWork W2033089666 @default.
• W12291014 hasRelatedWork W2053806269 @default.
• W12291014 hasRelatedWork W2150885028 @default.
• W12291014 hasRelatedWork W2230048083 @default.
• W12291014 hasRelatedWork W2496924072 @default.
• W12291014 hasRelatedWork W2531052508 @default.
• W12291014 hasRelatedWork W2547590150 @default.
• W12291014 hasRelatedWork W2801448674 @default.
• W12291014 hasRelatedWork W2889691785 @default.
• W12291014 hasVolume "122" @default.
• W12291014 isParatext "false" @default.
• W12291014 isRetracted "false" @default.
• W12291014 magId "12291014" @default.
• W12291014 workType "article" @default.